Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fortress Biotech ( (FBIO) ) has issued an update.
On March 30, 2026, Fortress Biotech announced that its majority-owned subsidiary Cyprium Therapeutics closed the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds under a previously agreed asset purchase arrangement. In connection with the transaction, Cyprium redeemed all outstanding shares of its 9.375% Perpetual Preferred Stock, simplifying its capital structure following receipt of the voucher proceeds.
Fortress, which owns 80.4% of Cyprium’s common stock on an as-converted basis, expects to receive at least $100 million over time from Cyprium via potential future dividends and intercompany arrangements, including repayment of intercompany debt, interest and accrued expenses. The ultimate amount Fortress will realize will depend on required payments to a National Institutes of Health institute, Cyprium’s tax liabilities, board-approved dividends, and other existing and future obligations, factors that could influence Fortress’s cash inflows and balance sheet flexibility.
The most recent analyst rating on (FBIO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Fortress Biotech stock, see the FBIO Stock Forecast page.
Spark’s Take on FBIO Stock
According to Spark, TipRanks’ AI Analyst, FBIO is a Neutral.
Overall score reflects a tug-of-war between weak cash-flow fundamentals (heavy ongoing burn and operating losses) and meaningful positive catalysts from recent regulatory wins and an encouraging earnings update tied to EMROSI traction and improving EBITDA. Technicals add moderate support longer-term but show near-term softness, while valuation offers limited help due to a negative P/E and no dividend.
To see Spark’s full report on FBIO stock, click here.
More about Fortress Biotech
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes therapeutics through a portfolio of majority- and minority-owned subsidiaries and partner companies. Its portfolio includes Cyprium Therapeutics, Inc., in which Fortress currently holds an 80.4% ownership stake on an as-converted basis, focusing on rare disease-related assets and associated financial instruments.
Average Trading Volume: 997,152
Technical Sentiment Signal: Sell
Current Market Cap: $85.66M
See more insights into FBIO stock on TipRanks’ Stock Analysis page.